{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fremanezumab&page=2", "query": { "intervention": "Fremanezumab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fremanezumab&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fremanezumab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T14:43:30.835Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02945046", "title": "A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Episodic Cluster Headache" ], "interventions": [ { "name": "Fremanezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 169, "start_date": "2017-01-19", "completion_date": "2019-05-13", "has_results": true, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-10-18T14:43:30.835Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02945046" }, { "nct_id": "NCT03347188", "title": "A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-Traumatic Headache" ], "interventions": [ { "name": "Fremanezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 87, "start_date": "2017-12-18", "completion_date": "2020-06-03", "has_results": true, "last_update_posted_date": "2022-12-13", "last_synced_at": "2026-10-18T14:43:30.835Z", "location_count": 33, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03347188" }, { "nct_id": "NCT07159750", "title": "Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Migraine", "Episodic Migraine", "Chronic Migraine, Headache" ], "interventions": [ { "name": "CGRP antibody or gepant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hospital Universitari Vall d'Hebron Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2024-01-02", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-18T14:43:30.835Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07159750" }, { "nct_id": "NCT04458857", "title": "A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Fremanezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 235, "start_date": "2020-07-15", "completion_date": "2024-03-13", "has_results": true, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-18T14:43:30.835Z", "location_count": 45, "location_summary": "Little Rock, Arkansas • Banning, California • Loma Linda, California + 38 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Banning", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04458857" }, { "nct_id": "NCT06173661", "title": "Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Migraine", "Menstrual Migraine", "Menstrually Related Migraine" ], "interventions": [ { "name": "Fremanezumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 15, "start_date": "2024-03-01", "completion_date": "2026-07-13", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-18T14:43:30.835Z", "location_count": 1, "location_summary": "Chestnut Hill, Massachusetts", "locations": [ { "city": "Chestnut Hill", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06173661" }, { "nct_id": "NCT02025556", "title": "A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Episodic Migraine Headache" ], "interventions": [ { "name": "LBR-101 High Dose", "type": "DRUG" }, { "name": "LBR-101 Low Dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 297, "start_date": "2014-01-31", "completion_date": "2015-03-31", "has_results": true, "last_update_posted_date": "2022-01-24", "last_synced_at": "2026-10-18T14:43:30.835Z", "location_count": 63, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02025556" }, { "nct_id": "NCT04464707", "title": "A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Fremanezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 292, "start_date": "2020-09-24", "completion_date": "2024-11-29", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-18T14:43:30.835Z", "location_count": 45, "location_summary": "Little Rock, Arkansas • Banning, California • Loma Linda, California + 37 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Banning", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04464707" }, { "nct_id": "NCT02638103", "title": "Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Fremanezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1890, "start_date": "2016-02-26", "completion_date": "2018-12-08", "has_results": true, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-10-18T14:43:30.835Z", "location_count": 90, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02638103" }, { "nct_id": "NCT07832266", "title": "Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cranial Nerve Injury", "Oropharyngeal Cancer" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Ajovy", "type": "DRUG" }, { "name": "Manual Therapy", "type": "OTHER" }, { "name": "IOPI device", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DEVICE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2027-03-01", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-18T14:43:30.835Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07832266" }, { "nct_id": "NCT04461795", "title": "Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David True", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2020-12-01", "completion_date": "2022-01-10", "has_results": true, "last_update_posted_date": "2022-04-13", "last_synced_at": "2026-10-18T14:43:30.835Z", "location_count": 2, "location_summary": "City of Saint Peters, Missouri • Springfield, Missouri", "locations": [ { "city": "City of Saint Peters", "state": "Missouri" }, { "city": "Springfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04461795" } ] }